Panel: Driving Diversity & Accessibility in Clinical Trials: From Study Design to Digital Execution
Session details:
As the landscape of clinical trials continues to evolve, ensuring diversity and digital accessibility from study design to site execution is not just a regulatory requirement, but a moral imperative. With a growing focus on equity, inclusion, and belonging in 2025, this session explores the intersection of clinical trial diversity and digital accessibility, highlighting the critical importance of designing inclusive, accessible trials for all patient populations, especially those with disabilities.
In this session, we will explore why diversity and digital accessibility matter, what actionable strategies can be applied to ensure inclusivity, and how inclusive design principles and digital accessibility standards (like WCAG) can be integrated across the entire clinical trial process—from study planning to site execution. Key topics will include:
- Why disability inclusion is crucial for health equity and trial diversity, with a focus on advancing science through diverse lived experiences, particularly for people with disabilities.
- What Information & Communication Technologies (ICT) are in scope and how digital accessibility design standards can break down barriers for patients, ensuring access, engagement, and adherence in clinical trials.
- How to apply inclusive design standards across the digital clinical trial ecosystem, ensuring a responsive, responsible, and equitable experience for all participants.
- Best practices for creating culturally sensitive and inclusive study designs that engage diverse patient populations.
- Effective recruitment strategies and community engagement to overcome barriers to diversity at the site level.
- Ensuring a patient-centric journey that fosters engagement and trust throughout the trial process, while also addressing key challenges in data collection, reporting, and site collaboration.
Join us for an in-depth exploration of how integrating diversity and accessibility in clinical trials is not just the right thing to do—it’s essential for the future of inclusive, equitable healthcare.
